PaperPaper Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma External Link Read MorePaper A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer External Link Read MorePaper Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. External Link Read MorePaper A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia PDF (1.15 MB) Read MorePaper Promising Activity Of Selinexor In The Treatment Of A Patient With Refractory Diffuse Large B-Cell Lymphoma And Central Nervous System Involvement External Link Read MorePaper Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom’s macroglobulinemia External Link Read MorePaper Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis External Link Read MorePaper A Phase I Clinical Trial of Single-Agent Selinexor in Acute Myeloid Leukemia External Link Read MorePaper Selective Inhibition of Nuclear Export with Selinexor in Patients with Non-Hodgkin’s Lymphoma External Link Read MorePaper Selinexor (KPT-330) induces tumor suppression through nuclear sequestration of IκB and down-regulation of survivin External Link Read More1 2 3 … 7 Next